利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.018 秒)

    Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies
    1.
    发明公开
    Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies 有权
    霍乱弧菌脂蛋白15（LP15）变体作为抗干扰在添加剂的tpn17基于免疫测定用于检测抗密螺旋体抗体

    公开(公告)号：EP2827147A1

    公开(公告)日：2015-01-21

    申请号：EP14177199.8

    申请日：2014-07-16

    申请人： Roche Diagnostics GmbH ,  F. Hoffmann-La Roche AG

    发明人： Faatz, Elke ,  Schaarschmidt, Peter ,  Schmitt, Urban ,  Scholz, Christian

    IPC分类号： G01N33/53 ,  G01N33/571

    CPC分类号： G01N33/6854 ,  C07K14/245 ,  C07K14/28 ,  C07K2319/35 ,  G01N33/5306 ,  G01N33/571 ,  G01N2333/20 ,  G01N2333/28 ,  G01N2469/20 ,  G01N2800/26

    摘要： The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 ( Vc Lp15) or a partial sequence thereof is used as a reagent for reduction of interference , i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a Vc Lp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said Vc Lp15-chaperone fusion polypeptide.

    摘要翻译： 本发明涉及用于检测抗体针对梅毒螺旋的的tpn17抗原的方法螺旋体在分离的样品worin霍乱弧菌脂蛋白15（VC LP15）或其部分序列组成的肽序列被用作试剂用于减少干扰的，即 为最大限度地减少假阳性结果。 此外，本发明涉及融合多肽，其包含一个VC LP15肽序列和分子伴侣，其使用如在免疫测定用于所述减少干扰的在添加剂的和用于最小化假阳性结果，并用试剂盒，用于检测抗体的抗梅毒螺旋体抗原 在分离的样品，其包括的tpn17抗原和Said Vc的LP15伴侣蛋白融合多肽。

    SlpA as a tool for recombinant protein and enzyme technology
    4.
    发明公开
    SlpA as a tool for recombinant protein and enzyme technology 有权
    SLPA ALS WERKZEUGFÜRRECOMBINANTE PROTEIN-UND ENZYM-TECHNOLOGIE

    公开(公告)号：EP2127679A1

    公开(公告)日：2009-12-02

    申请号：EP09006933.7

    申请日：2009-05-25

    申请人： Roche Diagnostics GmbH ,  F.HOFFMANN-LA ROCHE AG

    发明人： Faatz, Elke ,  Schaarschmidt, Peter ,  Schmitt, Urban ,  Scholz, Christian

    IPC分类号： A61K47/48 ,  C07K14/16 ,  C12N9/90 ,  G01N33/543 ,  G01N33/569

    CPC分类号： C12N15/62 ,  C12N9/90 ,  G01N33/536 ,  G01N33/54393 ,  Y02A50/57

    摘要： The present invention relates to a recombinant DNA molecule encoding a fusion protein comprising a SIpA chaperone and a target polypeptide wherein human FK506 binding proteins (FKBPs) are excluded as target polypeptides, a corresponding expression vector encoding said fusion protein as well as host cells transformed with said expression vector. Another aspect of the invention is a method for producing said fusion protein as well as a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide. A further aspect of the invention is the use of the recombinantly produced fusion protein as a binding partner or as a means for the reduction of interferences in an immunoassay. Further the invention relates to the use of the recombinantly produced fusion protein for immunization of laboratory animals in order to produce antibodies and to the use of the recombinantly produced fusion protein in the production of a vaccine. Yet another aspect is a method for the detection of an analyte in an immunoassay using a recombinantly produced fusion protein as well as a reagent kit containing a recombinantly produced fusion protein comprising a SlpA chaperone and a target polypeptide. A further aspect of the invention concerns the use of SlpA for the reduction of interferences in an immunoassay and its use as an additive in protein formulations and as a folding helper in biotechnological applications.

    摘要翻译： 本发明涉及编码融合蛋白的重组DNA分子，其包含SIpA伴侣和目标多肽，其中人FK506结合蛋白（FKBP）被排除为靶多肽，编码所述融合蛋白的相应表达载体以及用 表达载体。 本发明的另一方面是生产所述融合蛋白的方法以及重组产生的包含SlpA伴侣和靶多肽的融合蛋白。 本发明的另一方面是使用重组产生的融合蛋白作为结合配偶体或作为减少免疫测定中的干扰的手段。 此外，本发明涉及重组产生的融合蛋白用于免疫实验室动物以产生抗体的用途，以及在疫苗生产中使用重组产生的融合蛋白。 另一方面是使用重组产生的融合蛋白在免疫测定中检测分析物的方法以及含有重组产生的包含SlpA伴侣和靶多肽的融合蛋白的试剂盒。 本发明的另一方面涉及SlpA用于减少免疫测定中的干扰及其在蛋白质制剂中作为添加剂的用途以及在生物技术应用中作为折叠辅助剂的用途。

    Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies
    5.
    发明公开
    Recombinant expression of Rubella E1 envelope protein variants as chaperone fusion-proteins, and their use in the detection of anti-Rubella antibodies 有权
    风疹E1包膜蛋白的重组表达的变体作为伴侣融合蛋白和其用于检测抗风疹抗体的使用

    公开(公告)号：EP1780282A1

    公开(公告)日：2007-05-02

    申请号：EP06022216.3

    申请日：2006-10-24

    申请人： Roche Diagnostics GmbH ,  F.HOFFMANN-LA ROCHE AG

    发明人： Bollhagen, Ralf ,  Engel, Alfred ,  Faatz, Elke ,  Schaarschmidt, Peter ,  Scholz, Christian ,  Upmeier, Barbara ,  Zarnt, Toralf

    IPC分类号： C12N15/40 ,  C12N15/62 ,  C12N5/10 ,  C07K14/19 ,  G01N33/569

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C07K2319/35 ,  C12N2770/36222

    摘要： The present invention relates to a soluble Rubella E1 antigen and variants of this peptide characterized by lacking at the C-terminal end at least the transmembran region and the anchor segment as well as at least the amino acids 143 to 164 and containing at least the region spanning the disulfid-bridges Cys 349 - Cys 352 and Cys 368 - 401 whereas the N-terminus (Cys 349) of this region contains additionally at least 15 amino acids and / or the C-terminus (Cys 401) of this region contains additionally at least 8 amino acids of the adjacent Rubella E1 antigen sequence.
    The region spanning the disulfid-bridges Cys 349 - Cys 352 and Cys 368 - 401 contains at the N-terminus of this region (Cys 349) additionally at least 25, 30, 34 amino acids and / or at the C-terminus (Cys 401) of this region additionally at least 10, 11, 15, 25, 35 amino acids of the adjacent Rubella E1 antigen sequence.
    Furthermore, the invention relates to a recombinant DNA molecule, encoding a Rubella E1 antigen and variants, which are recombinantly expressed as a chaperone fusion-protein, refolded into a soluble and immunoreactive conformation and further used for the serological detection of anti-Rubella antibodies. In addition, the present invention discloses a method for the detection, determination and quantification of anti-Rubella antibodies of IgG and / or IgM subclass in a sample wherein the Rubella E1 antigen is used as a capture reagent and / or binding partner for the antibodies. The invention comprises further a diagnostic test and a reagent kit for the detection of anti-Rubella antibodies, containing at least one antigen of the Rubella E1 antigens.

    摘要翻译： 本发明涉及这种肽通过在C末端的至少跨膜区和锚定区段以及至少氨基酸143-164且含有至少该区域缺乏为特征的可溶性风疹E1抗原和变体 跨越二硫键桥的Cys 349 - 半胱氨酸352和Cys 368-401鉴于N-末端（半胱氨酸349）的此区域包含附加的至少15个氨基酸和/或C末端（半胱氨酸401）的此区域包含附加 邻风疹E1抗原的序列的至少8个氨基酸。 跨越二硫键的Cys 349的区域 - 的Cys 352和Cys 368-401包含该区域的N末端（半胱氨酸349）附加的至少25％，30，34个氨基酸和/或在C-末端（半胱氨酸 401）该区域的附加的至少10，11，15，25，风疹E1抗原的相邻序列的35个氨基酸。 进一步，本发明涉及一种重组DNA分子，编码风疹E1抗原和变体，它们是重组过表达作为伴侣融合蛋白，重折叠为可溶性和免疫反应性构象和进一步用于抗风疹抗体的血清学检测。 此外，本发明盘松动用于检测，确定和worin风疹E1抗原的样品中的IgG和/或IgM亚类的抗风疹抗体的定量的方法被用作捕获试剂和/或结合伴侣的抗体 ， 本发明还包括诊断测试和用于检测抗风疹抗体的试剂盒，含有该风疹E1抗原的至少一种抗原。